Posterior Urethral Valves (PUV)

1. Clinical Overview

Summary

Posterior urethral valves (PUV) are congenital obstructing membranous folds within the posterior urethra that represent the most common cause of bladder outlet obstruction in male infants and a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in children. [1,2] PUV occurs exclusively in males and affects approximately 1 in 5,000-8,000 male live births. [3]

The condition is increasingly diagnosed antenatally via ultrasound, typically manifesting as bilateral hydronephrosis, a distended thick-walled bladder, dilated posterior urethra (the pathognomonic "keyhole sign"), and in severe cases, oligohydramnios leading to pulmonary hypoplasia. [4,5] Approximately 90% of cases are Type I valves according to Young's classification, arising from abnormal insertion of the mesonephric duct into the developing urethra. [6]

Postnatal presentation varies from a palpable bladder and poor urinary stream to acute urinary retention or urosepsis. The pathophysiology centres on bladder outlet obstruction causing high-pressure bladder hypertrophy ("valve bladder"), bilateral hydroureteronephrosis, and progressive renal dysplasia. Vesicoureteric reflux (VUR) coexists in 40-50% of cases and may paradoxically serve as a "pop-off" mechanism protecting some renal units. [7,8]

Initial management involves bladder catheterisation to relieve obstruction, followed by definitive endoscopic valve ablation. In very small or unstable neonates, temporary vesicostomy may be performed. Despite intervention, 25-40% of boys with PUV progress to CKD stage 3-5, with nadir serum creatinine at 1 year of age being the most robust prognostic indicator. [9,10] Long-term complications include persistent bladder dysfunction (myogenic failure, detrusor overactivity), secondary VUR, urinary incontinence, and progression to ESRD requiring renal replacement therapy.

Lifelong multidisciplinary follow-up involving paediatric urologists, nephrologists, and specialist nurses is essential to monitor renal function, manage bladder dysfunction, and transition care appropriately into adulthood.

Key Facts

• Definition: Congenital membranous folds obstructing the posterior urethra, exclusively in males
• Incidence: 1 in 5,000-8,000 male live births [3]
• Classification: Type I valves (90%), Type III (10%), Type II (disputed/non-existent) [6]
• Antenatal Diagnosis: "Keyhole sign" on ultrasound (dilated bladder + posterior urethra), bilateral hydronephrosis, oligohydramnios [4,5]
• Vesicoureteric Reflux: Present in 40-50%, may act as "pop-off" mechanism [7,8]
• Treatment: Initial catheterisation → Endoscopic valve ablation (gold standard) or vesicostomy in small/unstable neonates [11,12]
• Prognosis: 25-40% develop CKD stage 3-5; nadir creatinine at 1 year is strongest predictor [9,10]
• Complications: Valve bladder dysfunction, CKD, ESRD, pulmonary hypoplasia, urinary incontinence [13,14]

Clinical Pearls

"Keyhole Sign is Pathognomonic": The antenatal ultrasound appearance of a dilated bladder continuous with a dilated posterior urethra resembles a keyhole and is virtually diagnostic of PUV in a male fetus. [4,5]

"Boys Only—No Exceptions": PUV is anatomically impossible in females due to differences in urethral development. Any apparent bladder outlet obstruction in a female fetus requires alternative diagnosis (e.g., urethral atresia, cloacal malformation).

"Catheterise First, Ask Questions Later": In a sick neonate with suspected PUV, immediate bladder drainage via urethral catheter (6-8 Fr feeding tube) is the priority to relieve obstruction, decompress the upper tracts, and allow initial stabilisation before imaging or definitive treatment.

"Nadir Creatinine is King": The serum creatinine nadir at 1 year of age (after maternal creatinine clearance) is the single most powerful predictor of long-term renal outcome. A nadir > 1.0 mg/dL (> 88 µmol/L) predicts high risk of progression to ESRD. [9,10]

"Pop-Offs Save Kidneys": Spontaneous decompression mechanisms (VUR, urinary ascites, bladder diverticulum, renal calyceal fornix rupture) may protect one or both kidneys by reducing intrarenal pressure, resulting in asymmetric renal damage. [7,8]

"Valve Bladder Never Forgets": Even after successful valve ablation, many boys develop permanent bladder dysfunction (myogenic failure, poor compliance, detrusor overactivity) requiring lifelong management with clean intermittent catheterisation (CIC) and anticholinergics. [15]

---

2. Epidemiology

Incidence and Prevalence

Geographic and Ethnic Variation

• No strong ethnic predilection has been consistently demonstrated
• Reported in all ethnic groups worldwide
• Some studies suggest slightly higher prevalence in Southeast Asian populations, though data are limited [16]

Associated Conditions

---

3. Aetiology and Pathophysiology

Embryological Basis

Posterior urethral valves result from abnormal development of the primitive urogenital sinus during weeks 8-12 of gestation. The prevailing theory suggests that Type I valves (90% of cases) arise from abnormal anterior insertion and fusion of the mesonephric (Wolffian) ducts into the posterior urethra at the level of the verumontanum. [6]

This creates obstructing membrane-like folds extending distally from the verumontanum toward the external urethral sphincter. Type III valves (10%) are thought to represent a distal urethral membrane or diaphragm with a central perforation. Type II valves (described as folds running cranially from verumontanum to bladder neck) are now considered non-obstructive radiological artefacts and likely do not exist as a true pathological entity. [6]

Young's Classification (1919)

Exam Detail: Molecular and Developmental Mechanisms:

While the precise genetic basis remains unclear, studies suggest multifactorial aetiology. Candidate genes involved in urogenital development (e.g., SHH, BMP4, WNT signalling pathways) have been implicated but no single causative mutation identified. Familial clustering is rare, suggesting predominantly sporadic occurrence with possible polygenic susceptibility.

Animal models (fetal lamb) have demonstrated that early urethral obstruction during nephrogenesis leads to obstructive nephropathy characterised by:

• Increased transforming growth factor-beta (TGF-β) expression
• Upregulation of renin-angiotensin-aldosterone system (RAAS)
• Tubular apoptosis and interstitial fibrosis
• Impaired nephrogenesis and reduced nephron number ("renal dysplasia")

These pathways explain why damage occurs in utero and is often irreversible despite postnatal relief of obstruction. [17]

Pathophysiological Cascade

The obstructing valves create a high-pressure bladder outlet obstruction that propagates damage in both antegrade (bladder) and retrograde (kidneys) directions:

1. Bladder Changes ("Valve Bladder")

• Detrusor hypertrophy: Compensatory smooth muscle thickening to overcome obstruction
• Trabeculation: Irregular bladder wall thickening visible on imaging
• Bladder diverticula: Mucosal herniation through weakened detrusor (may act as "pop-off")
• Myogenic failure: Chronic high-pressure leads to irreversible detrusor decompensation, poor contractility, and high post-void residuals
• Detrusor overactivity: Paradoxical overactivity coexisting with poor emptying [15]

2. Upper Tract Changes

• Bilateral hydroureteronephrosis: Transmission of high bladder pressure to ureters and collecting systems
• Vesicoureteric reflux (VUR): Secondary VUR from high intravesical pressure and abnormal ureteric orifices in 40-50% [7,8]
• Renal dysplasia: Abnormal renal architecture with cysts, immature glomeruli, and interstitial fibrosis
  • Most severe when obstruction is early and complete
  • Often asymmetric (one kidney may be better preserved, especially with unilateral VUR as "pop-off")
• Progressive CKD: Continued loss of nephron mass despite relief of obstruction due to hyperfiltration injury, fibrosis, and chronic inflammatory changes [17]

3. Antenatal Effects

• Oligohydramnios: Reduced fetal urine output → decreased amniotic fluid
• Pulmonary hypoplasia: Oligohydramnios in second trimester impairs alveolar development → respiratory insufficiency at birth (major cause of early mortality) [4]
• Potter sequence: Severe oligohydramnios → characteristic facies, limb positioning abnormalities

4. "Pop-Off" Mechanisms (Renoprotective)

Spontaneous decompression pathways paradoxically protect renal function in some cases by reducing sustained high intrarenal pressure: [7,8]

Boys with unilateral high-grade VUR may have marked asymmetry, with the refluxing kidney relatively well preserved and the non-refluxing kidney severely dysplastic from sustained obstruction. This counterintuitive phenomenon is well-recognised in PUV. [8]

---

4. Clinical Presentation

Antenatal Presentation

PUV is increasingly diagnosed on routine antenatal ultrasound (typically 18-20 week anomaly scan). Detection rates are 50-70% in centres with systematic screening protocols. [4,5]

Ultrasound Features

Exam Detail: Fetal Intervention Debate:

Fetal vesico-amniotic shunting (VAS) has been attempted in severe cases with oligohydramnios to decompress the bladder, restore amniotic fluid, and prevent pulmonary hypoplasia. However, randomised controlled trial evidence (PLUTO trial) showed no significant improvement in survival or renal outcomes compared to expectant management, and complications (shunt migration, infection, preterm labour) were common. [18]

Current consensus: VAS is not routinely recommended. Reserved for highly selected cases in specialist centres after multidisciplinary counselling. Delivery in a tertiary centre with neonatal surgery and NICU facilities is essential.

Postnatal Presentation

Presentation in the neonatal period or infancy varies depending on severity of obstruction and prenatal diagnosis.

Neonatal Presentation (0-28 days)

Infant/Childhood Presentation (Beyond Neonatal Period)

• Recurrent urinary tract infections (most common late presentation) [19]
• Failure to thrive (chronic renal impairment, UTIs)
• Daytime urinary incontinence (valve bladder dysfunction)
• Nocturnal enuresis
• Haematuria (UTI, stones)
• Rarely: acute abdomen (urinary ascites), hypertension (renal)

---

5. Clinical Examination

General Inspection

• Respiratory distress: Tachypnoea, intercostal recession (pulmonary hypoplasia in severe cases)
• Failure to thrive: Poor weight gain, decreased growth centiles
• Potter facies (severe oligohydramnios): Flattened nasal bridge, low-set ears, prominent epicanthal folds, micrognathia
• Limb positioning abnormalities: Talipes, limb contractures (oligohydramnios sequence)

Abdominal Examination

Genitourinary Examination

• Urethral meatus: Normal appearance (obstruction is posterior, not at meatus)
• Scrotum: Examine for undescended testes (may coexist)
• Observe voiding: Weak, dribbling stream; straining; prolonged duration

Cardiovascular Examination

• Blood pressure: Elevated in renal impairment
• Fluid status: Oedema (fluid overload in renal failure), dehydration (polyuric phase post-relief)

Systems Examination

• Respiratory: Signs of hypoplasia (persistent oxygen requirement, pneumothorax)
• Neurodevelopmental: Assess developmental milestones (chronic illness, CKD may affect development)

---

6. Differential Diagnosis

While the "keyhole sign" on antenatal ultrasound in a male fetus is virtually pathogn for PUV, other causes of bilateral hydronephrosis and bladder outlet obstruction must be considered.

Differential Diagnosis of Bladder Outlet Obstruction in Male Neonate

Differential Diagnosis of Bilateral Antenatal Hydronephrosis

---

7. Investigations

Initial Assessment (Neonate with Suspected PUV)

Immediate Bedside Tests

Blood Tests

Exam Detail: Interpreting Neonatal Creatinine:

• Neonatal serum creatinine at birth reflects maternal creatinine due to placental equilibration
• True neonatal renal function only assessable after 48-72 hours once maternal creatinine is cleared
• Persistently elevated or rising creatinine beyond 72 hours indicates intrinsic renal impairment
• Nadir creatinine (lowest creatinine achieved in first year of life, typically around 12 months) is the most powerful predictor of long-term renal outcome [9,10]

Nadir creatinine > 1.0 mg/dL (> 88 µmol/L) at 1 year: High risk of progression to CKD stage 4-5 and ESRD

Imaging

Postnatal Renal Ultrasound

Timing: Within 24-48 hours of birth (if antenatal diagnosis) or at presentation

Micturating Cystourethrogram (MCUG)

Gold standard diagnostic test for PUV. [20]

Timing:

• Urgency if diagnosis uncertain and patient unstable
• Otherwise: after initial stabilisation and urine sterile (ideally within first week of life)

Technique:

• Urethral catheterisation
• Contrast instillation into bladder via catheter
• Fluoroscopy during filling and voiding (catheter removed for voiding images)

Findings:

Exam Detail: Distinguishing Type I vs Type III PUV on MCUG:

• Type I: Dilated posterior urethra extends from bladder neck to level of external sphincter; valves arise at verumontanum
• Type III: Distal urethral membrane/diaphragm; obstruction more distal; less common

Definitive classification usually made at cystoscopy rather than MCUG.

DMSA Renal Scan (Technetium-99m Dimercaptosuccinic Acid)

Timing: After 3-6 months of age (or later, once stabilised)

Purpose:

• Assess differential renal function (% contribution of each kidney)
• Identify renal scarring or dysplasia
• Prognostic information (asymmetric function may indicate "pop-off" protection) [8]

Findings:

• Reduced uptake in dysplastic/scarred kidneys
• Asymmetric function common (e.g., 30% left, 70% right)

MAG3 Renogram (Mercaptoacetyltriglycine)

Purpose:

• Dynamic assessment of renal function and drainage
• Assess for ongoing obstruction post-valve ablation

Findings:

• Delayed tracer clearance
• Obstructed drainage curves

Long-Term Surveillance Investigations

---

8. Classification Systems

Young's Classification (1919)

The most widely used anatomical classification:

---

9. Management

Management Objectives

1. Immediate: Relieve bladder outlet obstruction and decompress upper tracts
2. Short-term: Prevent/treat urosepsis; correct metabolic derangement; optimise renal function
3. Definitive: Ablate obstructing valves
4. Long-term: Preserve renal function; manage bladder dysfunction; monitor for CKD progression

---

Management Algorithm

┌─────────────────────────────────────────────────────────────────────┐
│                    POSTERIOR URETHRAL VALVES                        │
│                      MANAGEMENT PATHWAY                             │
├─────────────────────────────────────────────────────────────────────┤
│                                                                     │
│  ANTENATAL DIAGNOSIS (Keyhole Sign on USS)                          │
│  ├─ Parental counselling (multidisciplinary)                        │
│  ├─ Serial USS monitoring (renal function, liquor volume)           │
│  ├─ Delivery planning at tertiary centre with paediatric urology    │
│  └─ Fetal intervention NOT routinely recommended [18]               │
│                                                                     │
│  ↓                                                                  │
│                                                                     │
│  IMMEDIATE POSTNATAL MANAGEMENT (within hours of birth/diagnosis)   │
│  ├─ ABC assessment (especially if pulmonary hypoplasia)             │
│  ├─ Urethral catheterisation (6-8 Fr feeding tube)                  │
│  │   • Immediate bladder decompression                              │
│  │   • Large urine drainage expected (200-500 mL or more)           │
│  │   • Leave catheter on free drainage                             │
│  ├─ Fluid resuscitation (IV fluids)                                 │
│  │   • Post-obstructive diuresis common                             │
│  │   • Monitor urine output closely; replace losses                 │
│  ├─ Bloods: U&E, creatinine, FBC, CRP, blood gas                    │
│  ├─ Urine culture (before starting antibiotics)                     │
│  ├─ IV antibiotics if sepsis suspected [19]                         │
│  │   • Broad-spectrum (e.g., gentamicin + amoxicillin/ampicillin)   │
│  └─ Correct metabolic acidosis and hyperkalaemia                    │
│                                                                     │
│  ↓                                                                  │
│                                                                     │
│  DIAGNOSTIC IMAGING (within 24-72 hours once stable)                │
│  ├─ Renal ultrasound (confirm bilateral hydronephrosis, bladder)    │
│  └─ MCUG (micturating cystourethrogram) [20]                        │
│      • Gold standard for diagnosis                                  │
│      • Perform after urine sterile (or cover with antibiotics)      │
│      • Confirms PUV, grade/laterality of VUR                        │
│                                                                     │
│  ↓                                                                  │
│                                                                     │
│  DEFINITIVE SURGICAL MANAGEMENT                                     │
│                                                                     │
│  Option 1: ENDOSCOPIC VALVE ABLATION (gold standard) [11]           │
│  ├─ Timing: Once baby stabilised (usually within 1-2 weeks)         │
│  ├─ Technique:                                                      │
│  │   • Paediatric cystoscopy under general anaesthesia              │
│  │   • Direct visualisation of valve leaflets                       │
│  │   • Ablation at 5 and 7 o'clock positions (Type I) or 12 o'clock│
│  │   • Use diathermy hook, cold knife, or laser                     │
│  │   • Catheter left in situ for 24-48 hours post-ablation          │
│  ├─ Success rate: > 90% with single procedure                        │
│  ├─ Complications: Urethral stricture (5-10%), bleeding, incomplete │
│  │   ablation requiring repeat procedure [11,21]                    │
│  └─ Confirmation: MCUG at 6-8 weeks (resolution of posterior        │
│      urethral dilatation; may still have VUR/hydronephrosis)        │
│                                                                     │
│  Option 2: TEMPORARY VESICOSTOMY [12,22]                            │
│  ├─ Indications:                                                    │
│  │   • Neonate too small for safe cystoscopy (less than 2 kg)                │
│  │   • Unstable, critically unwell (sepsis, respiratory failure)    │
│  │   • Failed valve ablation with persistent obstruction            │
│  │   • Severe urethral hypoplasia precluding instrumentation        │
│  ├─ Technique:                                                      │
│  │   • Surgical creation of cutaneous vesicostomy (bladder opening  │
│  │     onto anterior abdominal wall)                                │
│  │   • Allows bladder drainage without urethral catheterisation     │
│  │   • Temporary measure (closed once large enough for cystoscopy)  │
│  ├─ Closure: At 6-12 months, with concurrent valve ablation         │
│  └─ Outcomes: Equivalent renal outcomes to primary ablation [12,22] │
│                                                                     │
│  ↓                                                                  │
│                                                                     │
│  POST-ABLATION MANAGEMENT                                           │
│  ├─ Continue antibiotic prophylaxis (especially if VUR present)     │
│  ├─ Monitor renal function (serial creatinine, eGFR)                │
│  │   • Nadir creatinine at 1 year is key prognostic marker [9,10]  │
│  ├─ Monitor for post-obstructive diuresis (may last days-weeks)     │
│  ├─ Renal USS at 6-8 weeks (expect gradual improvement in           │
│  │   hydronephrosis, though rarely complete resolution)             │
│  ├─ DMSA scan (baseline differential function)                      │
│  └─ Repeat MCUG at 6-8 weeks (confirm valve ablation)               │
│                                                                     │
│  ↓                                                                  │
│                                                                     │
│  LONG-TERM FOLLOW-UP (LIFELONG)                                     │
│  ├─ Multidisciplinary team (paediatric urology, nephrology)         │
│  ├─ Monitor renal function (3-6 monthly):                           │
│  │   • Creatinine, eGFR, urea, electrolytes                         │
│  │   • 25-40% develop CKD stage 3-5 [9,10]                          │
│  ├─ Blood pressure monitoring (each visit)                          │
│  ├─ Urinalysis (UTI, proteinuria)                                   │
│  ├─ Renal USS (6-12 monthly, reduce if stable)                      │
│  ├─ Assess bladder function [15]:                                   │
│  │   • Voiding diary, flow rates, post-void residuals               │
│  │   • Urodynamics if symptoms (incontinence, recurrent UTI)        │
│  ├─ Manage "valve bladder"
dysfunction:                             │
│  │   • Anticholinergics (oxybutynin, solifenacin) for overactivity  │
│  │   • Clean intermittent catheterisation (CIC) if high residuals   │
│  │   • Alpha-blockers (prazosin) if bladder neck dysfunction        │
│  │   • Botulinum toxin (refractory detrusor overactivity)           │
│  │   • Augmentation cystoplasty (severe, refractory cases)          │
│  ├─ Manage VUR (if persistent, high-grade):                         │
│  │   • Antibiotic prophylaxis                                       │
│  │   • Consider ureteric reimplantation if breakthrough UTIs        │
│  ├─ Transition to adult services (late teens/early 20s):            │
│  │   • Adult nephrology (if CKD)                                    │
│  │   • Adult urology (bladder dysfunction)                          │
│  └─ Renal replacement therapy if ESRD:                              │
│      • Dialysis (haemodialysis or peritoneal dialysis)              │
│      • Renal transplantation (definitive; bladder must be optimised)│
│                                                                     │
└─────────────────────────────────────────────────────────────────────┘

---

Evidence-Based Management Protocols

Initial Resuscitation and Stabilisation

Immediate catheterisation is the cornerstone of initial management. [11,20]

• Use 6-8 Fr infant feeding tube (soft, flexible, atraumatic)
• Advance gently under aseptic technique
• If resistance encountered: do NOT force (risk urethral trauma)
  • Attempt with smaller catheter
  • Consider suprapubic catheterisation (ultrasound-guided) if urethral catheter fails
• Secure catheter and leave on free drainage
• Expect large volume urine output (bladder may hold 200-500 mL in neonate)
• Post-obstructive diuresis is common and may be profound:
  • Monitor urine output hourly
  • Replace urine losses with IV fluids (typically 0.45% saline + dextrose)
  • Monitor electrolytes closely (risk of hyponatraemia from excessive free water loss, or hyperkalaemia from renal impairment)

Antibiotic Therapy

Indications: [19]

• Clinical sepsis/urosepsis
• Positive urine culture
• Prophylaxis after catheterisation (some centres)

Choice:

• Broad-spectrum to cover urinary pathogens (E. coli, Klebsiella, Enterococcus)
• Neonatal regimen: Gentamicin + Amoxicillin/Ampicillin IV
• De-escalate based on culture sensitivities
• Duration: 7-10 days for confirmed UTI; 48-72 hours if prophylactic cover only

Long-term prophylaxis:

• Indicated if high-grade VUR present or recurrent UTIs
• Options: Trimethoprim, nitrofurantoin, cephalexin (dose according to age/weight)

Endoscopic Valve Ablation Technique

Procedure: [11,21]

• General anaesthesia
• Paediatric cystoscope (6.5-9 Fr) with camera and working channel
• Identify verumontanum (landmark)
• Visualise valve leaflets (typically 5 and 7 o'clock positions in Type I PUV)
• Ablate using:
  • Diathermy hook/electrode (most common)
  • Cold knife (Seldinger technique)
  • Holmium laser (increasingly used; precise, less scarring risk)
• Ablate at valve base (avoid excessive depth → risk urethral stricture, sphincter injury)
• Post-procedure: urethral catheter 24-48 hours; observe for bleeding, retention

Confirmation of success:

• MCUG at 6-8 weeks: resolution of dilated posterior urethra
• Clinical improvement: better stream, reducing hydronephrosis on USS
• Incomplete ablation occurs in 10-20%; repeat cystoscopy if persistent obstruction

Management of Vesicoureteric Reflux in PUV

VUR coexists in 40-50% and management is controversial. [7,8]

Key principles:

• VUR may be protective ("pop-off") → do NOT routinely correct immediately
• Many cases of VUR resolve spontaneously after valve ablation (reduced bladder pressure)
• Indications for surgical correction (ureteric reimplantation):
  • Persistent high-grade VUR (grade IV-V) after valve ablation
  • Recurrent breakthrough UTIs despite antibiotic prophylaxis
  • Progressive renal scarring on DMSA

Conservative approach:

• Antibiotic prophylaxis
• Repeat MCUG at 12-24 months to assess VUR resolution
• Surveillance USS and DMSA

Management of Bladder Dysfunction ("Valve Bladder")

Despite successful valve ablation, many boys develop irreversible bladder dysfunction due to myogenic failure from chronic obstruction. [15]

Presentations:

• Daytime urinary incontinence
• Nocturnal enuresis
• Recurrent UTIs (high post-void residuals)
• Poor urinary stream despite patent urethra

Investigations:

• Voiding diary (frequency, volumes, incontinence episodes)
• Uroflowmetry + post-void residual USS
• Urodynamic studies (cystometry):
  • Reduced bladder capacity
  • Poor compliance (high-pressure bladder)
  • Detrusor overactivity
  • Detrusor underactivity (myogenic failure)

Treatment ladder:

1. Behavioural: Timed voiding, double voiding, pelvic floor physiotherapy
2. Pharmacological:
   • Anticholinergics (oxybutynin, solifenacin, tolterodine) for detrusor overactivity
   • Alpha-blockers (prazosin, tamsulosin) for bladder neck dysfunction
3. Clean intermittent catheterisation (CIC): If high post-void residuals, recurrent UTI, or poor emptying
4. Botulinum toxin A (intravesical): For refractory detrusor overactivity
5. Surgical:
   • Bladder neck procedures (if outlet obstruction persists)
   • Augmentation cystoplasty (bladder augmentation with bowel segment) for severe, refractory small-capacity, high-pressure bladder
   • Mitrofanoff procedure (continent catheterisable channel) if CIC via urethra difficult

---

10. Complications

Antenatal and Perinatal

Renal Complications

Exam Detail: Nadir Creatinine as Prognostic Marker: [9,10]

The serum creatinine nadir at 1 year of age is the single most powerful predictor of long-term renal outcome in PUV. This represents the lowest creatinine achieved after postnatal clearance of maternal creatinine and reflects baseline renal function before hyperfiltration and progressive CKD.

Prognostic thresholds:

• Nadir creatinine less than 0.8 mg/dL (less than 70 µmol/L): Good prognosis; low risk of ESRD
• Nadir creatinine 0.8-1.0 mg/dL (70-88 µmol/L): Moderate risk
• Nadir creatinine > 1.0 mg/dL (> 88 µmol/L): High risk of progression to ESRD (> 50% by adolescence/early adulthood)

This marker allows early identification of high-risk patients requiring intensive nephrology follow-up, early renal transplant work-up, and pre-emptive management strategies (blood pressure control, dietary protein restriction, ACE inhibitor therapy).

Bladder and Lower Urinary Tract Complications

Surgical Complications

Psychosocial Complications

• Developmental delay (chronic illness, hospitalisations)
• School absenteeism (frequent medical appointments, UTIs)
• Incontinence-related social stigma (especially school-age children)
• Body image concerns (stomas, catheters)
• Anxiety/depression (chronic disease burden, uncertain prognosis)
• Family stress (caregiver burden, financial impact)

Support:

• Paediatric psychology input
• Family support groups
• School liaison (continence plans, medical absence accommodations)
• Transition planning to adult services

---

11. Prognosis and Outcomes

Factors Influencing Prognosis

Good Prognostic Factors

• Normal amniotic fluid volume (antenatally)
• Absence of renal dysplasia on USS/DMSA
• Nadir creatinine less than 0.8 mg/dL (less than 70 µmol/L) at 1 year [9,10]
• Unilateral high-grade VUR (pop-off mechanism protecting one kidney) [8]
• Early antenatal diagnosis and planned delivery at tertiary centre
• Good differential function on DMSA (both kidneys > 40%)

Poor Prognostic Factors

• Oligohydramnios (antenatally) [4]
• Bilateral renal dysplasia (echogenic kidneys, cortical cysts)
• Nadir creatinine > 1.0 mg/dL (> 88 µmol/L) at 1 year [9,10]
• Absence of "pop-off" mechanisms (no VUR, ascites, diverticulum)
• Delayed diagnosis (presentation with urosepsis, renal failure in infancy)
• Pulmonary hypoplasia (major cause of neonatal mortality) [4]
• Bilateral poor renal function on DMSA (less than 40% total function)

Long-Term Outcomes

Renal Outcomes

Exam Detail: Natural History of Renal Function in PUV:

Even boys with initially good renal function post-ablation may experience progressive decline over years due to:

• Hyperfiltration injury: Remaining nephrons hyper-filter to compensate for reduced renal mass → glomerulosclerosis
• Focal segmental glomerulosclerosis (FSGS): Common histological finding in PUV kidneys
• Persistent bladder dysfunction: High-pressure voiding → ongoing upper tract damage despite valve ablation
• Recurrent UTIs and VUR: Chronic pyelonephritis

Long-term surveillance into adulthood is essential. Some patients with normal function in childhood develop CKD in their 30s-40s. [17]

Bladder Outcomes

• 50-70% have persistent bladder dysfunction despite successful valve ablation [15]
• Manifestations: incontinence, urgency, frequency, recurrent UTI, nocturia
• Many require lifelong anticholinergics and/or clean intermittent catheterisation
• 5-10% require bladder augmentation (augmentation cystoplasty) for refractory small, high-pressure bladder

Quality of Life

• Generally good if renal function preserved and bladder dysfunction well-managed
• Significant impact from:
  • Urinary incontinence (social, school, relationships)
  • CKD burden (diet, medications, hospital visits)
  • ESRD (dialysis dependency, transplant)
• Transition to adult services critical (late teens/early 20s); risk of loss to follow-up

Mortality

• Neonatal mortality: 5-10% (predominantly pulmonary hypoplasia) [4]
• Long-term mortality: Increased in those progressing to ESRD; transplantation improves survival

---

12. Prevention and Screening

Antenatal Screening

• Routine antenatal ultrasound at 18-20 weeks (anomaly scan) detects 50-70% of PUV cases [4,5]
• Keyhole sign is pathognomonic in male fetus
• Serial USS monitoring in confirmed cases:
  • Assess liquor volume (oligohydramnios progression)
  • Monitor renal parenchymal appearance (dysplasia)
  • Plan delivery at tertiary centre with paediatric urology and neonatal intensive care

Fetal Intervention

• Vesico-amniotic shunting (VAS) has been attempted to:

  • Decompress fetal bladder
  • Restore amniotic fluid (prevent pulmonary hypoplasia)
  • Protect fetal kidneys

• PLUTO trial (randomised controlled trial) showed no significant benefit in survival or renal outcomes; complications common [18]

Current consensus:

• VAS not routinely recommended
• Consider only in highly selected cases (severe oligohydramnios, favourable fetal urine biochemistry) in specialist fetal medicine centres
• Parental counselling regarding uncertain benefit and risks

Genetic Counselling

• PUV is sporadic in > 95% of cases; familial clustering rare
• Recurrence risk in subsequent male pregnancies extremely low (less than 1%)
• No specific genetic test available

---

13. Guidelines and Evidence

Key Guidelines

Key Evidence

Landmark Studies

1. Young et al. (1919): Original description and classification of posterior urethral valves; classification remains in use. [6]

2. Warshaw et al. (1982): First description of nadir creatinine as prognostic marker in PUV.

3. Parkhouse et al. (1988): Long-term follow-up study demonstrating high incidence of CKD and ESRD in PUV cohorts; highlighted need for lifelong surveillance.

4. Coleman et al. (2015): Defined modern nadir creatinine thresholds; nadir > 1.0 mg/dL at 1 year predicts high ESRD risk. [10]

5. PLUTO Trial (2013): Randomised trial of fetal vesico-amniotic shunting vs conservative management; no benefit demonstrated. [18]

6. Khondker et al. (2023): Systematic review and meta-analysis of "pop-off" mechanisms (VUR, ascites, diverticulum); confirmed renoprotective effect. [7,8]

Recent Advances

• Holmium laser ablation: Increasingly used for valve ablation; more precise, potentially lower stricture rate than diathermy [21]
• Urodynamic studies: Better characterisation of valve bladder phenotypes guiding tailored management [15]
• Biomarkers: Urine NGAL, KIM-1 being investigated as prognostic markers (not yet routine clinical use)
• Genetic studies: Genome-wide association studies (GWAS) seeking susceptibility loci; no definitive genes identified yet

---

14. Examination Focus

Viva Voce Questions and Model Answers

Exam Detail: Question 1: "A male neonate is referred to you with antenatal diagnosis of bilateral hydronephrosis and a 'keyhole sign' on ultrasound. How do you approach this patient?"

Model Answer:

This presentation is highly suggestive of posterior urethral valves, the most common cause of bladder outlet obstruction in male infants.

Immediate management (first hours):

• ABC assessment—particularly respiratory status if oligohydramnios/pulmonary hypoplasia suspected
• Urethral catheterisation with 6-8 Fr feeding tube to decompress bladder and upper tracts
• Anticipate large urine drainage and post-obstructive diuresis; monitor urine output closely
• IV fluid resuscitation; replace urine losses
• Blood tests: U&E, creatinine (interpret cautiously—reflects maternal creatinine initially), FBC, CRP, blood gas
• Urine culture (before antibiotics)
• IV antibiotics if sepsis suspected (gentamicin + ampicillin)
• Correct metabolic acidosis, hyperkalaemia

Diagnostic confirmation (next 24-72 hours):

• Postnatal renal ultrasound (confirm bilateral hydronephrosis, assess kidneys, bladder)
• MCUG (micturating cystourethrogram) once urine sterile—gold standard to confirm PUV, assess for VUR

Definitive treatment:

• Endoscopic valve ablation once stabilised (typically within 1-2 weeks)
• Alternative: temporary vesicostomy if neonate too small (less than 2 kg) or unstable

Long-term:

• Lifelong multidisciplinary follow-up (paediatric urology, nephrology)
• Monitor renal function—nadir creatinine at 1 year is key prognostic marker
• Assess for bladder dysfunction, VUR, CKD progression
• 25-40% develop CKD; 10-30% progress to ESRD

---

Question 2: "What is the significance of nadir creatinine in posterior urethral valves?"

Model Answer:

Nadir creatinine is the lowest serum creatinine level achieved in the first year of life, typically measured around 12 months of age, and is the most powerful predictor of long-term renal outcome in boys with PUV.

Why measure at 1 year?

• At birth, neonatal creatinine reflects maternal creatinine (placental equilibration)
• True neonatal renal function assessable after 48-72 hours
• By 1 year, maternal influence eliminated and baseline renal function established before hyperfiltration/CKD progression begins

Prognostic thresholds (Coleman et al., 2015):

• Nadir less than 0.8 mg/dL (less than 70 µmol/L): Good prognosis; low ESRD risk
• Nadir 0.8-1.0 mg/dL (70-88 µmol/L): Moderate risk
• Nadir > 1.0 mg/dL (> 88 µmol/L): High risk—over 50% progress to ESRD by adolescence/early adulthood

Clinical utility:

• Identifies high-risk patients requiring:
  • Intensive nephrology follow-up
  • Early transplant work-up and donor identification
  • Aggressive blood pressure control, ACE inhibitor therapy
  • Dietary modification (protein restriction)
• Counselling families regarding long-term prognosis and need for potential renal replacement therapy

References: Coleman et al. (2015), Delefortrie et al. (2022). [9,10]

---

Question 3: "What are 'pop-off' mechanisms in PUV and why are they important?"

Model Answer:

Pop-off mechanisms are spontaneous decompression pathways that develop in response to high-pressure bladder outlet obstruction in PUV, allowing urine to escape the obstructed system and paradoxically protect renal function by reducing sustained high intrarenal pressure.

Types of pop-off mechanisms:

1. Vesicoureteric reflux (VUR): 40-50% of PUV cases; especially unilateral high-grade VUR—refluxing kidney often better preserved than non-refluxing kidney
2. Urinary ascites: 5-10%; from spontaneous bladder or ureteric perforation, with free intraperitoneal urine
3. Large bladder diverticulum: Acts as low-pressure reservoir, reducing pressure transmission to upper tracts
4. Urinoma: Localised urine collection from calyceal fornix rupture

Clinical importance:

• Pop-off mechanisms are renoprotective, not complications to be immediately corrected
• Boys with unilateral VUR often have asymmetric renal damage—refluxing kidney relatively preserved, non-refluxing kidney severely dysplastic
• Systematic review/meta-analysis (Khondker et al., 2023) confirmed better long-term renal outcomes in presence of pop-offs
• Management implication: Do not rush to correct VUR surgically; allow spontaneous resolution post-valve ablation; only intervene for persistent high-grade VUR with recurrent UTIs

References: Khondker et al. (2023), Arredondo Montero et al. (2024). [7,8]

---

Question 4: "Describe the surgical technique of endoscopic valve ablation."

Model Answer:

Endoscopic valve ablation is the gold standard definitive treatment for PUV.

Timing: Once neonate stabilised, typically within 1-2 weeks of birth (or at diagnosis if presenting later)

Pre-operative preparation:

• General anaesthesia
• Urine sterile (or on antibiotic cover)
• Informed parental consent (risks: bleeding, stricture, incomplete ablation, sphincter injury)

Equipment:

• Paediatric cystoscope (6.5-9 Fr) with camera and working channel
• Ablation instrument: diathermy hook/electrode (most common), cold knife, or Holmium laser

Technique:

1. Urethral catheterisation and cystoscope insertion under direct vision
2. Identify landmarks: Verumontanum (midline elevation on posterior urethral wall)
3. Visualise valve leaflets:
   • Type I valves: typically bilateral folds extending distally from posterior aspect of verumontanum at approximately 5 and 7 o'clock positions
   • Appear as "sail-like" membranes during antegrade flow
4. Ablation:
   • Incise/ablate valve leaflets at their base (attachment to urethral wall)
   • For Type I: ablate at 5, 7, and sometimes 12 o'clock positions
   • Avoid excessive depth (risk urethral stricture, external sphincter injury)
   • Holmium laser increasingly preferred (precise, less thermal damage, lower stricture rate)
5. Confirm adequate ablation: Valve leaflets should be completely divided; posterior urethra should appear patent
6. Post-procedure:
   • Urethral catheter left in situ for 24-48 hours
   • Monitor for haematuria (common, usually self-limiting)
   • Remove catheter once urine clear

Confirmation of success:

• MCUG at 6-8 weeks: Resolution of dilated posterior urethra; valve leaflets no longer visible
• Clinical: Improved urinary stream, reducing hydronephrosis on USS

Complications:

• Urethral stricture: 5-10%
• Incomplete ablation requiring repeat procedure: 10-20%
• Bleeding: Usually minor
• Sphincter injury/incontinence: Rare if careful technique

References: Nasir et al. (2011), Ibrahim et al. (2025). [11,21]

---

Question 5: "A 5-year-old boy with known PUV, status post-valve ablation at birth, presents with recurrent urinary tract infections and daytime incontinence. How do you investigate and manage?"

Model Answer:

This presentation suggests "valve bladder" dysfunction, a common long-term complication affecting 50-70% of boys despite successful valve ablation, resulting from irreversible myogenic changes due to chronic obstruction.

Investigations:

1. Urinalysis and culture: Rule out active UTI
2. Renal function: U&E, creatinine (assess for CKD progression)
3. Bladder diary: Frequency, voided volumes, incontinence episodes, fluid intake
4. Uroflowmetry: Assess flow pattern (obstructed vs normal vs interrupted)
5. Post-void residual ultrasound: High residuals suggest poor emptying
6. Renal ultrasound: Assess hydronephrosis (resolution vs persistence suggesting ongoing obstruction or VUR)
7. Micturating cystourethrogram (MCUG): If not done recently—confirm complete valve ablation, assess VUR
8. Urodynamic studies (cystometry): Gold standard to characterise bladder dysfunction:
   • Bladder capacity (small, normal, large)
   • Compliance (normal vs poor compliance/high pressure)
   • Detrusor overactivity (involuntary contractions)
   • Detrusor underactivity/myogenic failure (poor contractility)
   • Outlet obstruction (if incomplete ablation or stricture)

Typical urodynamic findings in valve bladder:

• Small capacity
• Poor compliance (high-pressure bladder)
• Detrusor overactivity ± detrusor underactivity (mixed picture)

Management:

Conservative/behavioural:

• Timed voiding regimen (every 2-3 hours)
• Double voiding technique
• Ensure adequate hydration (avoid concentrated urine irritating bladder)
• Treat constipation (can worsen bladder dysfunction)

Pharmacological:

• Anticholinergics for detrusor overactivity: oxybutynin, solifenacin, tolterodine
• Alpha-blockers if bladder neck dysfunction: prazosin, tamsulosin
• Antibiotic prophylaxis (if recurrent UTIs): trimethoprim, nitrofurantoin

Clean intermittent catheterisation (CIC):

• Indicated if high post-void residuals (> 20-30% bladder capacity) or refractory incontinence/UTIs
• Teach child/parents technique; typically 4-6 times daily

Minimally invasive:

• Botulinum toxin A (intravesical injection) for refractory detrusor overactivity

Surgical (if refractory to above):

• Augmentation cystoplasty (bladder augmentation with bowel segment) for severe small, high-pressure bladder
• Mitrofanoff procedure (continent catheterisable channel from umbilicus/lower abdomen to bladder) if CIC via urethra difficult

Repeat MCUG:

• If persistent VUR, consider ureteric reimplantation (especially if high-grade and recurrent pyelonephritis)

Long-term follow-up:

• Continue monitoring renal function (risk CKD progression)
• Multidisciplinary input: paediatric urology, continence nurse specialists, psychology support

References: de Jesus (2022), Bingham et al. (2025). [15]

---

15. Patient and Layperson Explanation

What Are Posterior Urethral Valves?

Posterior urethral valves (PUV) are thin flaps of tissue inside the tube that carries urine out of the bladder (called the urethra) in baby boys. These flaps block the flow of urine, like a faulty valve that won't open properly. This blockage causes urine to back up into the bladder, and then into the tubes (ureters) and kidneys, which can damage them.

Who Gets It?

• PUV only happens in boys (not girls), because of the way boys' urinary systems develop before birth
• It affects about 1 in 5,000 to 8,000 baby boys
• It is something the baby is born with (congenital), not something that develops later

How Is It Diagnosed?

Many cases are now found before the baby is born on routine pregnancy ultrasound scans (usually around 18-20 weeks). The ultrasound may show:

• A very full, thick-walled bladder
• A "keyhole shape" where the bladder and blocked tube meet
• Swollen kidneys (hydronephrosis)
• Sometimes low amniotic fluid (the water around the baby)

If not found before birth, PUV may be diagnosed after birth if the baby has:

• A weak urine stream or difficulty passing urine
• A swollen tummy (from a full bladder)
• Urine infections
• Breathing problems (in severe cases, if the baby's lungs didn't develop properly due to low amniotic fluid)

What Tests Are Needed?

After birth, the doctors will do:

• Ultrasound scan of the kidneys and bladder
• Special X-ray test called an MCUG (micturating cystourethrogram): A small tube is placed in the bladder, contrast dye is put in, and X-ray pictures are taken while the baby urinates. This shows the blockage clearly.
• Blood tests to check kidney function

How Is It Treated?

Immediate treatment:

• A small, soft tube (catheter) is gently placed into the bladder to drain the urine and relieve the blockage straight away
• Fluids are given through a drip
• Antibiotics may be given if there is an infection

Definitive treatment:

• Surgery (endoscopic valve ablation): This is usually done within the first few weeks of life. A tiny camera (cystoscope) is passed into the urethra under general anaesthetic, and the surgeon uses a small instrument to cut or burn away the blocking valve tissue. This is keyhole surgery—no cuts on the skin.
• In very small or unwell babies, a temporary operation called a vesicostomy may be done instead. This creates a small opening from the bladder to the tummy, allowing urine to drain into a nappy. This is closed later when the baby is bigger.

What Happens Afterwards?

Most babies recover well from the surgery, but they need lifelong follow-up because:

• Some boys develop kidney problems over time, even after successful surgery. About 1 in 4 to 1 in 3 boys with PUV will have reduced kidney function (chronic kidney disease) as they grow up.
• Many boys have bladder problems (finding it hard to control urine, needing to go frequently, wetting themselves) because the bladder was damaged by the blockage. This may need medicines or learning to use a catheter to empty the bladder.
• Regular check-ups are needed to monitor kidney function, blood pressure, and bladder health.

What Is the Long-Term Outlook?

• Many boys with PUV do very well and lead normal, active lives.
• Some will need ongoing treatment for bladder problems.
• A small number (about 1 in 10 to 1 in 3, depending on severity) may eventually need dialysis or a kidney transplant if their kidneys fail over time.
• Early diagnosis and treatment give the best chance of a good outcome.

What Support Is Available?

• Paediatric urology and kidney specialist teams will follow your child regularly.
• Specialist nurses can help with bladder management and catheter training.
• Support groups and charities (e.g., ERIC—Education and Resources for Improving Childhood Continence) provide information and peer support.

Key Message for Parents

Posterior urethral valves are a serious condition, but with early diagnosis, prompt treatment, and careful long-term follow-up, most boys can have a good quality of life. The most important thing is to attend all follow-up appointments so that any problems can be caught and treated early.

---

16. References

Primary Literature (PubMed Indexed)

1. Hodges SJ, Patel B, McLorie G, Atala A. Posterior urethral valves. ScientificWorldJournal. 2009 Oct 14;9:1119-26. doi: 10.1100/tsw.2009.127. PMID: 19838598.

2. Bingham G, Leslie SW, Rentea RM. Posterior Urethral Valves. 2025 Jan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32809716.

3. Nasir AA, Ameh EA, Abdur-Rahman LO, et al. Posterior urethral valve. World J Pediatr. 2011 Aug;7(3):205-16. doi: 10.1007/s12519-011-0325-9. PMID: 21822988.

4. Bernardes LS, Aksnes G, Saada J, et al. Keyhole sign: how specific is it for the diagnosis of posterior urethral valves? Ultrasound Obstet Gynecol. 2009 Oct;34(4):419-23. doi: 10.1002/uog.6413. PMID: 19642115.

5. Roy S, Colmant C, Cordier AG, et al. [Contribution of ultrasound signs for the prenatal diagnosis of posterior urethral valves: Experience of 3 years at the maternity of the Bicêtre Hospital]. J Gynecol Obstet Biol Reprod (Paris). 2016 May;45(5):425-33. doi: 10.1016/j.jgyn.2015.06.015. PMID: 25980903. (French)

6. Young HH, Frontz WA, Baldwin JC. Congenital obstruction of the posterior urethra. J Urol. 1919;3:289-365. (Classic reference; PMID not available for 1919 publication)

7. Khondker A, Kim K, Najmabadi BT, et al. Posterior urethral valves, pressure pop-offs, and kidney function: systematic review and meta-analysis. World J Urol. 2023 Jul;41(7):1859-1867. doi: 10.1007/s00345-023-04449-0. PMID: 37330439.

8. Arredondo Montero J, Pérez Riveros BP, Rico Jiménez M, et al. Pop-off mechanisms as renoprotective mediators in children with posterior urethral valves: A systematic review and meta-analysis. J Pediatr Urol. 2024 Feb;20(1):26.e1-26.e10. doi: 10.1016/j.jpurol.2023.09.020. PMID: 37852807.

9. Delefortrie T, Ferdynus C, Paye-Jaouen A, et al. Nadir creatinine predicts long-term bladder function in boys with posterior urethral valves. J Pediatr Urol. 2022 Apr;18(2):169.e1-169.e7. doi: 10.1016/j.jpurol.2022.01.017. PMID: 35184944.

10. Coleman R, King T, Nicoara CD, et al. Nadir creatinine in posterior urethral valves: How high is low enough? J Pediatr Urol. 2015 Dec;11(6):362.e1-5. doi: 10.1016/j.jpurol.2015.06.011. PMID: 26292912.

11. Ibrahim Y, Mohamed A, Iqbal S, et al. Outcome of Endoscopic Ablation of Late-childhood Posterior Urethral Valves: Case Series and Literature Review. J Pediatr Surg. 2025 Jun;60(6):161596. doi: 10.1016/j.jpedsurg.2024.161596. PMID: 40180181.

12. Hofmann A, Haider M, Cox A, et al. Is Vesicostomy Still a Contemporary Method of Managing Posterior Urethral Valves? Children (Basel). 2022 Jan 21;9(2):135. doi: 10.3390/children9020135. PMID: 35204859.

13. Klaus R, Lange-Sperandio B. Chronic Kidney Disease in Boys with Posterior Urethral Valves-Pathogenesis, Prognosis and Management. Biomedicines. 2022 Aug 5;10(8):1862. doi: 10.3390/biomedicines10081862. PMID: 36009441.

14. Weaver JK, Rickard M, Weinstein C, et al. Predicting chronic kidney disease progression in children with posterior urethral valves. J Pediatr Urol. 2024 Nov 22;S1477-5131(24)00592-X. doi: 10.1016/j.jpurol.2024.11.011. PMID: 39648111.

15. de Jesus LE. Bladder dysfunction depends on many variables in children with posterior urethral valves. Int Braz J Urol. 2022 Jan-Feb;48(1):13-27. doi: 10.1590/S1677-5538.IBJU.2021.0349. PMID: 34735084.

16. Ekarat P, Attawettayanon W, Limratchapong C, et al. Posterior urethral valve in thai boys. BMC Pediatr. 2023 Sep 7;23(1):442. doi: 10.1186/s12887-023-04266-8. PMID: 37679663.

17. Farrugia MK. Fetal bladder outflow obstruction: Interventions, outcomes and management uncertainties. Early Hum Dev. 2020 Nov;150:105177. doi: 10.1016/j.earlhumdev.2020.105177. PMID: 32978001.

18. Morris RK, Malin GL, Quinlan-Jones E, et al. Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. Lancet. 2013 Nov 2;382(9903):1496-506. doi: 10.1016/S0140-6736(13)60992-7. PMID: 23953766. (Note: PMID from original PLUTO trial; also referenced in Farrugia review [17])

19. Belko NA, Pohl HG. Pediatric Urinary Tract Infections. Urol Clin North Am. 2024 Nov;51(4):459-471. doi: 10.1016/j.ucl.2024.06.004. PMID: 39349021.

20. Manzoni C, Valentini AL. Posterior urethral valves. Rays. 2002 Apr-Jun;27(2):131-4. PMID: 12696266.

21. Shekar PA, Yadav P, Srivastava A, et al. "When ablation goes wrong"- urethral strictures after ablation of posterior urethral valves-characteristics, management and outcomes". J Pediatr Urol. 2020 Dec;16(6):838.e1-838.e8. doi: 10.1016/j.jpurol.2020.08.027. PMID: 32981860.

22. Dias T, Sairam S, Kumarasiri S. Ultrasound diagnosis of fetal renal abnormalities. Best Pract Res Clin Obstet Gynaecol. 2014 Apr;28(3):403-15. doi: 10.1016/j.bpobgyn.2014.01.009. PMID: 24524801.

Guidelines

• European Association of Urology (EAU). EAU Guidelines on Paediatric Urology. 2023. Available at: https://uroweb.org/guidelines/paediatric-urology
• British Association of Paediatric Urologists (BAPU). Consensus Statements on Posterior Urethral Valves. 2019.

---